10:48
Dr Amazed - Tesamorelin DECIMATES Visceral Fat and MORE
This Is Not Covered - Dr. Ashley Froese
Overview
This video explains tesamorelin, a peptide that targets and reduces dangerous visceral fat. It details how tesamorelin works by stimulating the pituitary gland to release more growth hormone, which specifically targets visceral fat due to its higher concentration of growth hormone receptors. The video also highlights tesamorelin's benefits for liver health, its role in mitochondrial browning for fat burning, and its potential to reduce neuroinflammation and improve cognitive function. Finally, it discusses the peptide's approved use for HIV-related lipodystrophy, the reasons for its limited accessibility, and potential side effects, while emphasizing the risks associated with untreated visceral fat and fatty liver.
How was this?
Save this permanently with flashcards, quizzes, and AI chat
Chapters
- Tesamorelin is a peptide that effectively reduces visceral fat, the dangerous fat surrounding organs.
- It works by mimicking growth hormone-releasing hormone (GHRH) to stimulate the pituitary gland.
- Visceral fat has more growth hormone receptors than other fat types, making it more responsive to GHRH signaling.
- This targeted action differentiates tesamorelin from other GHRH analogs.
Understanding how tesamorelin targets visceral fat explains its unique effectiveness and why it's a powerful tool for addressing a major health risk.
Visceral fat is described as 'inflammatory sticky fat around your organs that has the potential to kill you faster' and has more receptors for growth hormone than other fat.
- Tesamorelin is a full-length GHRH analog, unlike shorter fragments like sermorelin or CJC-1295.
- Its stability allows it to remain in the body longer (around 40 minutes), enabling it to reach receptors outside the brain.
- Tesamorelin triggers mitochondrial browning and UCP1 in fat cells, essentially turning them into heat-generating furnaces.
- This process converts 'lazy' white fat into metabolically active brown fat, increasing energy expenditure.
This detailed mechanism reveals how tesamorelin actively burns fat for energy, rather than just mobilizing it, offering a more profound metabolic effect.
Mitochondrial browning is explained using the analogy of installing a furnace inside a storage locker, giving a previously dormant space a high-energy purpose.
- Tesamorelin significantly reduces liver fat deposits, with studies showing a 37% reduction in 12 months.
- It activates PGC1-alpha, a master regulator of mitochondrial biogenesis, leading to increased mitochondria and fatty acid oxidation in the liver.
- The peptide downregulates inflammatory cytokines, which are often produced by visceral fat.
- Tesamorelin has shown promise in improving cognitive function by reducing neuroinflammation and enhancing prefrontal cortex activity.
These additional benefits highlight tesamorelin's systemic impact, demonstrating its potential to improve overall metabolic health and cognitive performance.
A study showed that participants given tesamorelin had a 37% reduction in fatty liver deposits after 12 months.
- Tracking visceral fat using methods like DEXA scans, InBody scans, or home analyzers (like Hume Body Pod) is recommended.
- Tesamorelin is FDA-approved only for HIV-associated lipodystrophy, not general weight loss.
- Its high cost ($6,000 for the branded version) and specific approval limit accessibility.
- The peptide's original development involved proving its efficacy for a specific condition to secure pharmaceutical approval and patents.
Understanding the approved uses and accessibility barriers explains why tesamorelin isn't widely prescribed and why individuals might seek it through alternative channels.
Tesamorelin was approved for HIV patients experiencing visceral fat buildup due to their treatments, a condition known as lipodystrophy.
- Potential side effects include fluid shifts, swelling, tingling, and carpal tunnel syndrome.
- A significant risk is that tesamorelin, by promoting growth, could potentially fuel existing or hidden tumors.
- Individuals with a history of cancer or strong family history should exercise extreme caution.
- Despite risks, the dangers of untreated visceral fat and fatty liver are also substantial, leading some to seek tesamorelin.
- The video concludes by emphasizing the peptide's potent effects and the current limitations on its use.
Awareness of risks and the comparison to the risks of inaction are crucial for informed decision-making regarding tesamorelin use.
Tesamorelin can cause fluid retention, leading to swelling and tingling in the hands and feet, and even carpal tunnel syndrome.
Key takeaways
- Tesamorelin is a powerful peptide that specifically targets and reduces dangerous visceral fat by enhancing growth hormone release.
- Its mechanism involves not just mobilizing fat but also actively burning it through mitochondrial browning and UCP1 activation.
- Beyond fat loss, tesamorelin offers significant benefits for liver health and cognitive function by reducing inflammation and improving metabolic processes.
- The peptide's limited FDA approval for HIV-related lipodystrophy creates accessibility challenges and high costs for general use.
- Potential users must weigh the risks, including fluid retention and the possibility of stimulating tumor growth, against the severe health risks posed by untreated visceral fat and fatty liver.
- Monitoring visceral fat levels through methods like DEXA or InBody scans is important for tracking progress when using such interventions.
- The medical system's structure and patent laws dictate why a highly effective compound like tesamorelin is not widely available for common conditions.
Key terms
TesamorelinVisceral fatGrowth hormone-releasing hormone (GHRH)Pituitary glandMitochondrial browningUCP1 (Uncoupling protein 1)PGC1-alphaInflammatory cytokinesNeuroinflammationHIV-associated lipodystrophy
Test your understanding
- How does tesamorelin's mechanism of action differ from other growth hormone-releasing peptides, and why is this difference significant for targeting visceral fat?
- Explain the process of mitochondrial browning and how tesamorelin induces it to promote fat loss.
- What are the key benefits of tesamorelin beyond visceral fat reduction, particularly concerning liver and brain health?
- Why is tesamorelin not widely prescribed for general fat loss, and what are the primary barriers to its accessibility?
- What are the main risks associated with tesamorelin use, and how should individuals with a history of cancer approach its consideration?